Augmented transgene expression in transformed cells using a parvoviral hybrid vector

Cancer Gene Therapy

Volumn 15, Issue 4, 2008, Pages 252-267

  Kruger L ^a   Eskerski, H ^b   Dinsart, C ^a   Cornelis, J ^a   Rommelaere, J ^a   Haberkorn, U ^b   Kleinschmidt, J A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

AAV; H1PV; Hybrid vector; Parvovirus

Indexed keywords

CARMUSTINE; CISPLATIN; ENZYME; MITOMYCIN C; NONSTRUCTURAL PROTEIN 1; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CELL KILLING; CELL TRANSFORMATION; CELL TYPE; CONTROLLED STUDY; FEMALE; GENE; GENE CASSETTE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; IRRADIATION; LIVER; LIVER CELL CARCINOMA; LONG TERMINAL REPEAT; NONHUMAN; NS1 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; STIMULATION; TRANSGENE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS HYBRID;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; GENETIC VECTORS; HELA CELLS; HUMANS; PARVOVIRUS; RATS; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; MIRIDAE; PARVOVIRUS; RATTUS;

EID: 40549123369     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701113     Document Type: Article

References (100)

1. Muzyczka N, Warrington Jr KH. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 2005; 16: 408-416.
2. Buning H, Ried MU, Perabo L, Gerner FM, Huttner NA, Enssle J et al. Receptor targeting of adeno-associated virus vectors. Gene Therapy 2003; 10: 1142-1151.
3. Wickham TJ. Ligand-directed targeting of genes to the site of disease. Nat Med 2003; 9: 135-139.
4. Waterkamp DA, Muller OJ, Ying Y, Trepel M, Kleinschmidt JA. Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med 2006; 8: 1307-1319.
5. Khare PD, Rosales AG, Bailey KR, Russell SJ, Federspiel MJ. Epitope selection from an uncensored peptide library displayed on avian leukosis virus. Virology 2003; 315: 313-321.
6. Bupp K, Roth MJ. Targeting a retroviral vector in the absence of a known celltargeting ligand. Hum Gene Therapy 2003; 14: 1557-1564.
7. Hartl I, Schneider RM, Sun Y, Medvedovska J, Chadwick MP, Russell SJ et al. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Therapy 2005; 12: 918-926.
8. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003; 21: 1040-1046.
9. Perabo L, Buning H, Kofler DM, Ried MU, Girod A, Wendtner CM et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 2003; 8: 151-157.
10. Kottke T, Qiao J, Diaz RM, Ahmed A, Vroman B, Thompson J et al. The perforindependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles. Gene Therapy 2006; 13: 1166-1177.
11. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L et al. Tumortargeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigenspecific T cells. Nat Med 2005; 11: 1073-1081.
12. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209-214.
13. Toniatti C, Bujard H, Cortese R, Ciliberto G. Gene therapy progress and prospects: transcription regulatory systems. Gene Therapy 2004; 11: 649-657.
14. Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting. Trends Genet 2000; 16: 174-181.
15. Dupont F, Avalosse B, Karim A, Mine N, Bosseler M, Maron A et al. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector. Gene Therapy 2000; 7: 790-796.
16. Gancberg D, Zeicher M, Bakkus M, Dupont F, Leo O, Moser M et al. Oncoselective transduction of CD80 and CD86 in tumor cell lines using an autonomous recombinant parvovirus. Anticancer Res 2000; 20: 1825-1832.
17. Russell SJ, Brandenburger A, Flemming CL, Collins MK, Rommelaere J. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 1992; 66: 2821-2828.
18. Cornelis JJ, Salome N, Dinsart C, Rommelaere J. Vectors based on autonomous parvoviruses: novel tools to treat cancer? J Gene Med 2004; 6(Suppl 1): S193-S202.
19. Roberts MS, Lorence RM, Groene WS, Bamat MK. Naturally oncolytic viruses. Curr Opin Mol Ther 2006; 8: 314-321.
20. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2: 938-950.
21. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002; 9: 961-966.
22. Liu XY. Targeting gene-virotherapy of cancer and its prosperity. Cell Res 2006; 16: 879-886.
23. Cornelis JJ, Lang SI, Stroh-Dege AY, Balboni G, Dinsart C, Rommelaere J. Cancer gene therapy through autonomous parvovirus-mediated gene transfer. Curr Gene Ther 2004; 4: 249-261.
24. Maxwell IH, Terrell KL, Maxwell F. Autonomous parvovirus vectors. Methods 2002; 28: 168-181.
25. Blechacz B, Russell SJ. Parvovirus vectors: use and optimisation in cancer gene therapy. Expert Rev Mol Med 2004; 6: 1-24.
26. Rommelaere J, Cornelis JJ. Antineoplastic activity of parvoviruses. J Virol Methods 1991; 33: 233-251.
27. McKisic MD, Paturzo FX, Smith AL. Mouse parvovirus infection potentiates rejection of tumor allografts and modulates T cell effector functions. Transplantation 1996; 61: 292-299.
28. Perros M, Deleu L, Vanacker JM, Kherrouche Z, Spruyt N, Faisst S et al. Upstream CREs participate in the basal activity of minute virus of mice promoter P4 and in its stimulation in ras-transformed cells. J Virol 1995; 69: 5506-5515.
29. Fuks F, Deleu L, Dinsart C, Rommelaere J, Faisst S. ras oncogene-dependent activation of the P4 promoter of minute virus of mice through a proximal P4 element interacting with the Ets family of transcription factors. J Virol 1996; 70: 1331-1339.
30. Deleu L, Fuks F, Spitkovsky D, Horlein R, Faisst S, Rommelaere J. Opposite transcriptional effects of cyclic AMP-responsive elements in confluent or p27KIP overexpressing cells versus serum-starved or growing cells. Mol Cell Biol 1998; 18: 409-419.
31. Warrington Jr KH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006; 119: 571-603.
32. Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD, Siegal GP. Adeno-associated virus for cancer gene therapy. Cancer Res 2001; 61: 6313-6321.
33. Li C, Bowles DE, van Dyke T, Samulski RJ. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther 2005; 12: 913-925.
34. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
35. Salvetti A, Oreve S, Chadeuf G, Favre D, Cherel Y, Champion-Arnaud P et al. Factors influencing recombinant adeno-associated virus production. Hum Gene Ther 1998; 9: 695-706.
36. Chen YQ, de Foresta F, Hertoghs J, Avalosse BL, Cornelis JJ, Rommelaere J. Selective killing of simian virus 40-transformed human fibroblasts by parvovirus H-1. Cancer Res 1986; 46: 3574-3579.
37. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106: 761-771.
38. Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 1990; 50: 2840-2847.
39. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973; 51: 1409-1416.
40. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijnden-van Raaij AJ, van der Saag PT et al. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 1995; 6: 1151-1161.
41. Ohnuki Y, Marnell MM, Babcock MS, Lechner JF, Kaighn ME. Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res 1980; 40: 524-534.
42. McAllister RM, Isaacs H, Rongey R, Peer M, Au W, Soukup SW et al. Establishment of a human medulloblastoma cell line. Int J Cancer 1977; 20: 206-212.
43. Kestler J, Neeb B, Struyf S, Van Damme J, Cotmore SF, D'Abramo A et al. cis requirements for the efficient production of recombinant DNA vectors based on autonomous parvoviruses. Hum Gene Ther 1999; 10: 1619-1632.
44. Zolotukhin S, Potter M, Hauswirth WW, Guy J, Muzyczka N. A 'humanized' green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J Virol 1996; 70: 4646-4654.
45. Heilbronn R, Burkle A, Stephan S, zur Hausen H. The adeno-associated virus rep gene suppresses herpes simplex virus-induced DNA amplification. J Virol 1990; 64: 3012-3018.
46. Groner B, Herrlich P, Kennedy N, Ponta H, Rahmsdorf U, Hynes NE. Delimitation of a DNA sequence which confers inducibility by glucocorticoid hormones. J Cell Biochem 1982; 20: 349-357.
47. Grimm D. Production methods for gene transfer vectors based on adeno-associated virus serotypes. Methods 2002; 28: 146-157.
48. Grimm D, Kay MA, Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 2003; 7: 839-850.
49. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
50. Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol 2005; 79: 2528-2540.
51. Wrzesinski C, Tesfay L, Salome N, Jauniaux JC, Rommelaere J, Cornelis J et al. Chimeric and pseudotyped parvoviruses minimize the contamination of recombinant stocks with replication-competent viruses and identify a DNA sequence that restricts parvovirus H-1 in mouse cells. J Virol 2003; 77: 3851-3858.
52. Faisst S, Perros M, Deleu L, Spruyt N, Rommelaere J. Mapping of upstream regulatory elements in the P4 promoter of parvovirus minute virus of mice. Virology 1994; 202: 466-470.
53. Gu Z, Plaza S, Perros M, Cziepluch C, Rommelaere J, Cornelis JJ. NF-Y controls transcription of the minute virus of mice P4 promoter through interaction with an unusual binding site. J Virol 1995; 69: 239-246.
54. Pereira DJ, McCarty DM, Muzyczka N. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection. J Virol 1997; 71: 1079-1088.
55. Pereira DJ, Muzyczka N. The adeno-associated virus type 2 p40 promoter requires a proximal Sp1 interaction and a p19 CArG-like element to facilitate Rep transactivation. J Virol 1997; 71: 4300-4309.
56. Weger S, Wistuba A, Grimm D, Kleinschmidt JA. Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins. J Virol 1997; 71: 8437-8447.
57. Kyostio SR, Wonderling RS, Owens RA. Negative regulation of the adeno-associated virus (AAV) P5 promoter involves both the P5 rep binding site and the consensus ATP-binding motif of the AAV Rep68 protein. J Virol 1995; 69: 6787-6796.
58. Clark KR, Voulgaropoulou F, Fraley DM, Johnson PR. Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 1995; 6: 1329-1341.
59. Tamayose K, Hirai Y, Shimada T. A new strategy for large-scale preparation of hightiter recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum Gene Ther 1996; 7: 507-513.
60. Fisher KJ, Gao G, Weitzman MD, DeMatteo R, Burda J, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
61. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a ratelimiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
62. Xiao W, Warrington Jr KH, Hearing P, Hughes J, Muzyczka N. Adenovirus facilitated nuclear translocation of adeno-associated virus type 2. J Virol 2002; 76: 11505-11517.
63. Daeffler L, Horlein R, Rommelaere J, Nuesch JP. Modulation of minute virus of mice cytotoxic activities through site-directed mutagenesis within the NS coding region. J Virol 2003; 77: 12466-12478.
64. Caillet-Fauquet P, Perros M, Brandenburger A, Spegelaere P, Rommelaere J. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO J 1990; 9: 2989-2995.
65. Corbau R, Duverger V, Rommelaere J, Nuesch JP. Regulation of MVM NS1 by protein kinase C: impact of mutagenesis at consensus phosphorylation sites on replicative functions and cytopathic effects. Virology 2000; 278: 151-167.
66. Mousset S, Ouadrhiri Y, Caillet-Fauquet P, Rommelaere J. The cytotoxicity of the autonomous parvovirus minute virus of mice nonstructural proteins in FR3T3 rat cells depends on oncogene expression. J Virol 1994; 68: 6446-6453.
67. Kanazawa T, Urabe M, Mizukami H, Okada T, Kume A, Nishino H et al. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAVHSVtk/ganciclovir on cancer cells. Cancer Gene Ther 2001; 8: 99-106.
68. Peng D, Qian C, Sun Y, Barajas MA, Prieto J. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J Hepatol 2000; 32: 975-985.
69. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H et al. Suicide gene therapy using AAVHSVtk/ ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Therapy 2003; 10: 51-58.
70. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 1995; 92: 5719-5723.
71. Alexander J, Russell D, Miller A. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol 1994; 68: 8282-8287.
72. Alexander IE, Russell DW, Spence AM, Miller AD. Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum Gene Ther 1996; 7: 841-850.
73. Sanlioglu S, Benson P, Engelhardt JF. Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology 2000; 268: 68-78.
74. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005; 30: 71-88.
75. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K et al. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 2005; 79: 609-614.
76. Tullis GE, Burger LR, Pintel DJ. The minor capsid protein VP1 of the autonomous parvovirus minute virus of mice is dispensable for encapsidation of progeny singlestranded DNA but is required for infectivity. J Virol 1993; 67: 131-141.
77. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
78. Summerford C, Bartlett JS, Samulski RJ. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
79. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a coreceptor for infection by adeno-associated virus 2. Nat Med 1999; 5: 71-77.
80. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 2006; 80: 9831-9836.
81. Isayeva T, Kumar S, Ponnazhagan S. Anti-angiogenic gene therapy for cancer (review). Int J Oncol 2004; 25: 335-343.
82. Qing K, Khuntirat B, Mah C, Kube DM, Wang XS, Ponnazhagan S et al. Adenoassociated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J Virol 1998; 72: 1593-1599.
83. Qing K, Wang XS, Kube DM, Ponnazhagan S, Bajpai A, Srivastava A. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc Natl Acad Sci USA 1997; 94: 10879-10884.
84. Qing K, Hansen J, Weigel-Kelley KA, Tan M, Zhou S, Srivastava A. Adenoassociated virus type 2-mediated gene transfer: role of cellular fkbp52 protein in transgene expression. J Virol 2001; 75: 8968-8976.
85. Qing K, Li W, Zhong L, Tan M, Hansen J, Weigel-Kelley KA et al. Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo. J Virol 2003; 77: 2741-2746.
86. Bashir T, Horlein R, Rommelaere J, Willwand K. Cyclin A activates the DNA polymerase delta-dependent elongation machinery in vitro: a parvovirus DNA replication model. Proc Natl Acad Sci USA 2000; 97: 5522-5527.
87. Hillgenberg M, Schlehofer JR, von Knebel Doeberitz M, Klein-Bauernschmitt P. Enhanced sensitivity of small cell lung cancer cell lines to cisplatin and etoposide after infection with adeno-associated virus type 2. Eur J Cancer 1999; 35: 106-110.
88. Duverger V, Sartorius U, Klein-Bauernschmitt P, Krammer PH, Schlehofer JR. Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int J Cancer 2002; 97: 706-712.
89. Schwarzbach MH, Eisold S, Burguete T, Willeke F, Klein-Bauernschmitt P, Schlehofer JR et al. Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild-type adeno-associated virus type 2 (AAV-2) infection. Int J Oncol 2002; 20: 1211-1218.
90. Kuntz-Simon G, Bashir T, Rommelaere J, Willwand K. Neoplastic transformation-associated stimulation of the in vitro resolution of concatemer junction fragments from minute virus of mice DNA. J Virol 1999; 73: 2552-2558.
91. Nuesch JP, Rommelaere J. NS1 interaction with CKII alpha: novel protein complex mediating parvovirus-induced cytotoxicity. J Virol 2006; 80: 4729-4739.
92. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. Gene Therapy 2005; 12: 873-880.
93. Vihinen-Ranta M, Suikkanen S, Parrish CR. Pathways of cell infection by parvoviruses and adeno-associated viruses. J Virol 2004; 78: 6709-6714.
94. Hauck B, Zhao W, High K, Xiao W. Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J Virol 2004; 78: 13678-13686.
95. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75: 6969-6976.
96. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006; 14: 316-327.
97. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5: 285-297.
98. Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 2005; 5: 299-310.
99. Perabo L, Endell J, King S, Lux K, Goldnau D, Hallek M et al. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J Gene Med 2006; 8: 155-162.
100. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adenoassociated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006; 24: 198-204.